Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose ...

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...

IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...

A comprehensive study of effective and resistant responses to a kidney cancer anti-PD-1 therapy found specific immune ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...